Intraductal Papilloma
Berrin Ustun
Garrison Pease
Genitourinary/Urologic (prostate, kidney, bladder, testicle, penis, adrenal gland) Pathology, with focus on one-on-one teaching at the scope with residents and medical students, along with quality assurance and quality improvement mind-set with emphasis on lab efficiency and patient-centered turn-around time.<quillbot-extension-portal></quillbot-extension-portal>
Genitourinary/Urologic Pathology, Quality Assurance and Improvement<quillbot-extension-portal></quillbot-extension-portal>
<p>Garrison Pease, MD, is an attending surgical pathologist and Assistant Professor, Pathology at Montefiore Einstein. His clinical focus centers on genitourinary and urologic pathology, with a focus on one-on-one teaching at the scope with residents and medical students. He is also focused on quality assurance and quality improvement with an emphasis on lab efficiency and patient-centered turn-around time.</p><p>After obtaining his Bachelor of Arts in biology from Saint John's University (Collegeville, MN) in 2009, Dr. Pease earned his Doctor of Medicine at the University of Minnesota in 2013. He completed his anatomic and clinical pathology residency at the University of University of Chicago - NorthShore in 2017, where he was Chief Resident in his final two years. Following this, Dr. Pease completed a general surgical pathology fellowship at Washington University – St. Louis in 2018, followed by a genitourinary pathology fellowship at the University of Washington in 2019.</p><p>Dr. Pease’s research is focused on genitourinary and urologic pathology and quality assurance and improvement. He has worked on the College of American Pathologists (CAP) self and peer-based laboratory inspections. His work has been published in several peer-reviewed journals and shared through abstracts and poster presentations nationally and internationally.</p><p>Dr. Pease is a Diplomate of the American Board of Pathology and is board certified in Anatomic and Clinical Pathology. He is a member of the United States and Canadian Academy of Pathology and the College of American Pathologists. In 2021, Dr. Pease won the Department of Pathology Outstanding Teaching Award from Montefiore Einstein's Pathology Residency program.</p>
Jennifer M. Oliver-Krasinski
Maureen P. McEvoy
breast cancer
Dr. McEvoy's clinical focus is on minimally invasive and oncoplastic techniques to achieve cosmetically acceptable outcomes while treating breast cancer surgically.
Young women with breast cancer and the prevention of lymphedema have been main focuses of interest in Dr. McEvoy’s research.
<p>Maureen P. McEvoy, MD, FACS, is a Breast Surgeon and Associate Professor at Montefiore Einstein. Her clinical focus is on minimally invasive and oncoplastic techniques to achieve cosmetically acceptable outcomes while treating breast cancer surgically. In addition, she focuses on lymphedema prevention in practice and research. As a physician, Dr. McEvoy educates patients about their diagnoses and helps them explore treatment options.</p><p>Dr. McEvoy received her Bachelor of Arts in mathematics and chemistry at New York University. She continued her studies at Albert Einstein College of Medicine, where she earned her Doctor of Medicine. Her postgraduate training began at Einstein with a surgical residency. During this time, Dr. McEvoy also participated in a clinical research fellowship at Memorial Sloan Kettering Cancer Center, which she completed before finishing up her residency. Her training continued at Massachusetts General Hospital with a yearlong fellowship in breast surgical oncology.</p><p>Young women with breast cancer and the prevention of lymphedema have been main focuses of interest in Dr. McEvoy’s research. She has presented her work on breast cancer nationally at numerous meetings and lectures. Her work has also been published in a number of peer-reviewed journals and articles.</p><p>Dr. McEvoy is board certified in general surgery and is a member of many professional organizations, such as the American College of Surgeons, the American Society of Breast Surgeons and the Society of Surgical Oncology. She received the Breast Journal Award at the Multidisciplinary Symposium on Breast Disease given to her by the American Society of Breast Disease.</p>
Chuanyong Lu
Javier A. Laurini
<span style="font-size:11.0pt;line-height:107%;font-family:'Calibri',sans-serif;">Dr. Laurini's clinical focus is on the study of tissue to diagnose inflammatory and neoplastic diseases of the breast, gynecologic tract and bone and soft tissues.</span>
<span style="font-size:11.0pt;line-height:107%;font-family:'Calibri',sans-serif;">Dr. Laurini's research focus follows his clinical interests in breast and gynecologic pathology.</span>
<p>Javier Ariel Laurini, MD, is Associate Professor, Pathology at Montefiore Einstein. Dr. Laurini's clinical focus is on the study of tissue to diagnose inflammatory and neoplastic diseases of the breast, gynecologic tract and bone and soft tissues.</p>
<p>After earning his Doctor of Medicine in 1995 from the University Of Salvador, School Of Medicine in Buenos Aires, Argentina, Dr. Laurini completed a residency in anatomic pathology in 1999 at the Center of Medical Education and Clinical Investigations (CEMIC) in Buenos Aires. Following this, he completed a three-month internship in hematopathology service at Massachusetts General Hospital. Dr. Laurini became Administrative Chief Resident in the department of pathology at CEMIC for one year before completing a surgical pathology fellowship at British Hospital in Buenos Aires in 2002. He then became a visiting clinician in the Department of Pathology, Mayo Clinic in Rochester before undergoing a combined anatomic and clinical pathology residency at the University of South Alabama College of Medicine, which he completed in 2010. Dr. Laurini then finished a fellowship in surgical pathology at the Mayo Clinic in 2011 before completing another fellowship in hematopathology at the University of Nebraska Medical Center in 2012.</p>
<p>Dr. Laurini's research focus follows his clinical interests in breast and gynecologic pathology. His work has been published in numerous original communications and peer-reviewed journals, articles and abstracts.</p>
<p>Dr. Laurini is board certified in Hematology and Anatomic and Clinical Pathology by the American Board Of Pathology. He is a Fellow of the College of American Pathologists and the American Society of Clinical Pathologists, and a member of the United States and Canadian Academy of Pathology. He is also part of the Mayo Clinic Alumni Association. Dr. Laurini has won multiple faculty teaching awards from the University of South Alabama and Wake Forest School of Medicine. In 2022 he won the Attending Teaching Award from Einstein.</p>
Rouzan G. Karabakhtsian
Editor, “Selected Abstracts in Anatomic Pathology†section of CAP Today, the College of American Pathologists monthly pathology news magazine.
Laura J. Hodges
Women’s interventional procedures, specifically uterine artery embolization for fibroid disease.
Women’s interventional procedures, specifically uterine artery embolization for fibroid disease.
<p>Laura J. Hodges, MD, is Attending Physician at Montefiore and Assistant Professor of Radiology at our Albert Einstein College of Medicine. Her practice specialty is breast imaging and interventional radiology, with a clinical focus on women’s interventional procedures, specifically uterine artery embolization for fibroid disease.</p><p>After receiving her Bachelor of Arts from University of Connecticut in 1985 and her Bachelor of Science from George Washington University in 1987, Dr. Hodges earned her Doctor of Medicine at Albert Einstein College of Medicine in 1994. Upon graduation, she then pursued postdoctoral training at Yale New Haven Hospital, completing a Radiology residency in 1999. She then attended Cornell Medical Center/Sloan Kettering Memorial Cancer Center where she completed a fellowship in Interventional Radiology in 2000.</p><p>Dr. Hodges’s research interests build on her clinical focus. She has published a case study on preoperative transcatheter embolization of abdominal pregnancy, as well as a number of abstracts on women’s interventional procedures.</p><p>Dr. Hodges is board certified and is a member of several professional societies, including the Society of Interventional Radiology, the American College of Radiology and the American Roentgen Ray Society.</p>
Susan A. Fineberg
Dr Fineberg's clinical focus is on the study of breast disease both neoplastic and benign.<quillbot-extension-portal></quillbot-extension-portal>
Dr. Fineberg's research focus is on the development of new predictive and prognostic biomarkers to be used in breast cancer patients to optimize clinical outcomes, investigation of the role of immunotherapy and standardization of pathologic practices amongst breast pathologists.<quillbot-extension-portal></quillbot-extension-portal>
<p>Lanjewar S, Patil P, <strong>Fineberg S. </strong>Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy- A survey of pathologists in academic institutions across the United States. Modern Pathol. 2019 .(33), 91-98. <a title="Read article" href="https://doi.org/10.1038/s41379-019-0326-5" target="_blank">https://doi.org/10.1038/s41379-019-0326-5</a></p>
<p>Kimberly J. Van Zee, MS, MD, Emily C. Zabor, MS, Rosemarie Di Donato, MD3, Bryan Harmon, MD, Jana Fox, MD, Monica Morrow, MD, Hiram S. Cody III, MD, <strong>Susan A. Fineberg, MD. </strong>A Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Vs Refined Oncotype DX Breast DCIS Score. Annals of Sugical Oncology . 2019 (26), 212-213. <a title="Read article" href="https://doi.org/10.1245/s10434-019-07537-4" target="_blank">https://doi.org/10.1245/s10434-019-07537-4</a></p>
<p>Didonato R, Shapiro N, Koenigsberg, D’Alfonso, T, Jaffer S, <strong>Fineberg S</strong>. Invasive Mucinous Carcinoma of the breast and Response Patterns After Neodjuvant Chemotherapy. Histopathology 2018 May; 72(6):965-973</p>
<p>Hazan, R, Suyamaa, K, Yao J, Liang H, Bernard , Loudig O Amgalm D, Mckimplson W, Phillops G, Segall J, Wang Y, <strong>Fineberg S,</strong> Norton L, Kitsis R. A paradoxical role for an Akt3 splice variant lacking serine 472 phosphorylation site in promoting apoptosis leading to suppression of mammary tumorigenesis. Cancer Research. 2018:78(1).103-114</p>
<p>Pearlman A, Upadhyay K, Cole K, Loke J, Suan K, <strong>Fineberg S,</strong> Freedland S, Shao Y, Ostrer H. Robust genomic copy number predictor of pan cancer metastasis. Genes and Cancer. 2018 <a title="Read article" href="https://doi.org/10.18632/genesandcancer.165" target="_blank">https://doi.org/10.18632/genesandcancer.165</a></p>
<p>Guo Tianhua, Shapiro Nella, Wang Yihong, <strong>Fineberg Susan</strong>. Pleomorphic lobular carcinoma in situ diagnosed by breast core biopsy: Clinicopathologic features and correlation with subsequent excision.Clinical Breast Cancer 2018 (4) e449-454 DOI: /10.1016/j.clbc.2017.10.004</p>
<p>Mclemore L Janakiram M, Albanese J, Shapiro N, Lo Y, Zang X, <strong>Fineberg S.</strong> An immunoscore using PD-L1, CD68 and tumor infiltrating lymphocytes (TILs) to predict response to neoadjuvant chemotherapy in invasive breast cancer. Appl Immunohistochem Mol Morphol.2018;26(9), 611-619. doi: 10.1097/PAI.0000000000000485</p>
<p>Maria-Vittoria Dieci, Nina Radosevic-Robin, <strong>Susan Fineberg</strong> et. al., on behalf of the International Immuno-Oncology Bio-marker Working Group* Update on Tumor Infiltrating Lymphocytes (TILs) in Breast Cancer, including recommendations to assess TILs in Residual Disease and DCIS: a report of the International Immuno-Oncology Biomarker Working group on Breast Cancer*. Seminars in Cancer Biology 2107:52.16-25. <a title="Persistent link using digital object identifier" href="https://doi.org/10.1016/j.semcancer.2017.10.003" target="_blank">https://doi.org/10.1016/j.semcancer.2017.10.003</a></p>
<p>Mantilla JG, Koenigsberg T, Reig B, Shapiro N, Villaneuva-Siles E, <strong>Fineberg S.</strong> Core biopsy of vascular neoplasms of the breast; Pathologic features , imaging and clinical findings. Amer J of Surg Pathol .2016; 40:1424-1434</p>
<p>Polley M, Leung S, Gao D, Mastropasqua M, Zabaglo L, Bartlett J, McShane L, Enos R, Badve S, Bane A, Borgquist S, <strong>Fineberg S</strong>, Lin M, Grabau A, Gutierrez C, Hugh J, Moriya T, Ohi Y, Osborne K, Penault-Llorca F, Piper T, Porter P, Sakatani T, Salgado R, Starczynski J, Lænkholm A, Viale G, Dowsett M, Hayes D, Nielsen T, on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG). An international study to increase concordance in Ki67 scoring. Modern Pathology .2015; 28 (6) :778. PubMed [citation] PMID 25698062</p>
<p>Diaz J, Stead L, Shapiro N, Newell R, Loudig O, Lo Y, Sparano J, <strong>Fineberg S</strong>. Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease. Breast Cancer Research and Treatment. 2013; 138 :91-97. PubMed [citation] PMID 23417359</p>
<p>Giricz, O, Reynolds P, Rammuauth A, Liu C, Wang T, Stead L, Childs G, Rohan T, Shapiro, N <strong>, Fineberg S,</strong> Kenny P, Loudig O. Has-miR375 is differentially expressed during lobular neoplasia and promotes loss of mammary acinar polarity. Journal of Pathology. 2012; 226 (1): 108-119 .PubMed [citation] PMID 21953071</p>
<p>Auerbach J, Kim M, <strong>Fineberg S</strong>. Can results of routine pathologic evaluation of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX Assay Recurrence Score result? Archives of Pathology and Laboratory Medicine. 2010; 134, (11): 1697-1701. PubMed [citation] PMID 21043825</p>
<p>Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, deng HF, Ament PS, <strong>Fineberg S,</strong> Pestell RG, Carasco N. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nature Medicine .2000; 6 (8): 871-878. PubMed [citation] PMID: 10932223</p>
<p>Casey M, Zimmerman J, Rosenblatt R, <strong>Fineberg S.</strong> Mastectomy without malignancy following carcinoma diagnosed by large core stereotactic breast biopsy. Modern Pathology.1997; 10 (12): 1209-1213. PubMed [citation] PMID: 9436965</p>
<p><strong>Fineberg S</strong>, Rosen P. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol. 1994; 102 (6): 757-762. PubMed [citation] PMID: 7801888</p>
<p>Susan Fineberg, MD, is an Attending Pathologist, Section Head Breast Pathology and Associate Professor, Pathology at Montefiore Einstein. An integral member of the multidisciplinary breast program leadership team, Dr. Fineberg’s clinical focus is the study of tissue to diagnose breast disease, both neoplastic and benign.</p><p>After receiving her Bachelor of Arts in chemistry from State University of New York (SUNY) Binghamton in 1983, Dr. Fineberg pursued her medical degree at SUNY Stonybrook School of Medicine, earning her Doctor of Medicine in 1987. She completed her anatomic and clinical pathology residency training at New York University Medical Center in 1992, followed by an oncologic surgical pathology fellowship at Memorial Sloan Kettering Cancer Center in 1993.</p><p>Dr. Fineberg's research focus includes biomarker development in invasive breast cancer, particularly in the neoadjuvant setting, prognostic and predictive markers for ductal carcinoma in situ progression and recurrence, the role of immune response in breast cancer progression, and standardization of practice among breast pathologists. She has over 60 peer-reviewed publications on breast disease, has authored book chapters on the subject and has presented her work at national meetings.</p><p>Dr. Fineberg is board certified and is an active member of many national and international pathology organizations including the United States and Canadian Academy of Pathology, the International Society of Breast Disease and the International TILs Immuno-Oncology Biomarker Working Group for Breast Cancer.</p>